France Predictive Genetic Testing Consumer Wellness Genomics Market

ID: MRFR/LS/50121-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026
France Predictive Genetic Testing and Consumer Wellness Genomics Market Research Report By Test Type (Predictive Testing, Consumer Genomics, Wellness Genomics), By Application (Breast & Ovarian Cancer, Cardiovascular Screening, Diabetic Screening & Monitoring, Colon Cancer, Parkinsonism/Alzheimer’s Disease, Urologic Screening/Prostate Cancer Screening, Orthopedic & Musculoskeletal, Others), and By Setting Type (Proteomic Testing, Metabolic Testing, Genomic Testing) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

France Predictive Genetic Testing Consumer Wellness Genomics Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)7.67%
2024 Market Size$ 174.38 Million
2025 Market Size$ 191.14 Million
2035 Market Size$ 393.17 Million

Key Players

23andMe
MyHeritage
Ancestry
Genetic Health
DNAfit
Invitae
Trends
  • Rising Consumer Awareness
  • Integration with Wellness Programs
  • Supportive Regulatory Environment
Opportunities
  • Increased Investment in Genomic Research
  • Rising Health Consciousness Among Consumers
  • Technological Advancements in Genetic Testing
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Health Risk Assessment
      2. 4.1.2 Carrier Testing
      3. 4.1.3 Ancestry Testing
      4. 4.1.4 Pharmacogenomics
      5. 4.1.5 Nutrigenomics
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Healthcare Providers
      2. 4.2.2 Direct-to-Consumer
      3. 4.2.3 Research Institutions
      4. 4.2.4 Pharmaceutical Companies
    3. 4.3 Healthcare, BY Technology (USD Million)
      1. 4.3.1 Next Generation Sequencing
      2. 4.3.2 Microarray Technology
      3. 4.3.3 Sanger Sequencing
      4. 4.3.4 PCR Technology
    4. 4.4 Healthcare, BY Consumer Demographics (USD Million)
      1. 4.4.1 Age Group
      2. 4.4.2 Gender
      3. 4.4.3 Income Level
      4. 4.4.4 Education Level
    5. 4.5 Healthcare, BY Regulatory Environment (USD Million)
      1. 4.5.1 Data Privacy Regulations
      2. 4.5.2 Testing Standards
      3. 4.5.3 Ethical Guidelines
      4. 4.5.4 Insurance Coverage
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 23andMe (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 MyHeritage (IL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Ancestry (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Genetic Health (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 DNAfit (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Invitae (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Fulgent Genetics (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 GenoPalate (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 GenePlanet (SI)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY APPLICATION
    3. 6.3 FRANCE MARKET ANALYSIS BY END USE
    4. 6.4 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 FRANCE MARKET ANALYSIS BY CONSUMER DEMOGRAPHICS
    6. 6.6 FRANCE MARKET ANALYSIS BY REGULATORY ENVIRONMENT
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY CONSUMER DEMOGRAPHICS, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY CONSUMER DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY REGULATORY ENVIRONMENT, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY REGULATORY ENVIRONMENT, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2026-2035 (USD Million)
      4. 7.2.4 BY CONSUMER DEMOGRAPHICS, 2026-2035 (USD Million)
      5. 7.2.5 BY REGULATORY ENVIRONMENT, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France Predictive Genetic Testing Consumer Wellness Genomics Market Segmentation

France Predictive Genetic Testing Consumer Wellness Genomics Market By Application (USD Million, 2026-2035)

  • Health Risk Assessment
  • Carrier Testing
  • Ancestry Testing
  • Pharmacogenomics
  • Nutrigenomics

France Predictive Genetic Testing Consumer Wellness Genomics Market By End Use (USD Million, 2026-2035)

  • France Predictive Genetic Testing Consumer Wellness Genomics Market Providers
  • Direct-to-Consumer
  • Research Institutions
  • Pharmaceutical Companies

France Predictive Genetic Testing Consumer Wellness Genomics Market By Technology (USD Million, 2026-2035)

  • Next Generation Sequencing
  • Microarray Technology
  • Sanger Sequencing
  • PCR Technology

France Predictive Genetic Testing Consumer Wellness Genomics Market By Consumer Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Income Level
  • Education Level

France Predictive Genetic Testing Consumer Wellness Genomics Market By Regulatory Environment (USD Million, 2026-2035)

  • Data Privacy Regulations
  • Testing Standards
  • Ethical Guidelines
  • Insurance Coverage

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035